A Long-term, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of a Modigraf Based Immunosuppression Regimen in Paediatric Solid Allograft Recipients

Trial Profile

A Long-term, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of a Modigraf Based Immunosuppression Regimen in Paediatric Solid Allograft Recipients

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Allotransplant rejection; Heart transplant rejection; Liver transplant rejection; Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PROGRESSION
  • Sponsors Astellas Pharma; Astellas Pharma Europe Ltd
  • Most Recent Events

    • 12 Dec 2017 This trial was discontinued in France, according to European Clinical Trials Database.
    • 08 Dec 2017 Status changed from active, no longer recruiting to discontinued.
    • 25 Oct 2017 This study has been discontinued Germany.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top